Company intelligence / Profile preview

Lindis Blood Care

Hennigsdorf, Brandenburg, Germany

Ownership: Private
Employees: ~25
Development stage: Other

Overview

REMOVE study (n>130, open-label, multicenter): CATUVAB® met all primary and secondary efficacy and safety endpoints with high statistical significance in intraoperative blood salvage for cancer surgery. Tumor cells were reliably removed from blood and safety profile was excellent. CE Mark (EU) and FDA authorization processes are ongoing[2][6].

Therapeutic areas: HematologyOncology
Modalities: Medical deviceAntibodyTrifunctional antibody
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Lindis Blood Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lindis Blood Care.

Explore the full profile